XML 32 R21.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company has determined that it operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology. The Company’s Chief Operating Decision Maker is the Chief Executive Officer (“CEO”). The CEO reviews profit and loss information on a consolidated basis to assess performance and make overall operating decisions as well as resource allocations.
All products are included in one segment because the Company’s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment.
The following table provides information about the Company’s significant expenses provided to the CEO and includes the reconciliation to loss before income taxes:
Three Months Ended March 31,
20252024
Net product revenue$52,511 $27,178 
Cost of products sold5,577 1,522 
Gross profit46,934 25,656 
Operating expenses:
Research and development expenses4,354 3,068 
General and administrative expenses16,739 27,145 
Selling and marketing expenses22,904 17,024 
Other segment items*5,938 4,454 
Total operating expenses49,935 51,691 
Operating loss(3,001)(26,035)
Investment and other income, net397 1,378 
Interest expense(2,238)(2,592)
Loss before income taxes$(4,842)$(27,249)
*For the three months ended March 31, 2025 and 2024, the other segment items category includes quality and regulatory expenses and medical affairs expenses.